Your browser doesn't support javascript.
loading
Patient Reported Outcomes Using Medical Cannabis for Managing Pain in Charcot-Marie-Tooth Disease.
Canals, Priscilla C; Aguilar, Alexia G; Carter, Gregory T; Shields, C Miyabe; Westerkamp, Andrew; D'Elia, Meg; Aldrich, Joy; Moore, Robert N; Moore, Allison T; Piper, Brian J.
Afiliación
  • Canals PC; Department of Medical Education, Geisinger Commonwealth School of Medicine, Scranton, PA, USA.
  • Aguilar AG; Department of Medical Education, Geisinger Commonwealth School of Medicine, Scranton, PA, USA.
  • Carter GT; Providence St Luke's Rehabilitation Medical Center, Hereditary Neuropathy Foundation Center of Excellence, Spokane, WA, USA.
  • Shields CM; Real Isolates LLC, Beverly, MA, USA.
  • Westerkamp A; Real Isolates LLC, Beverly, MA, USA.
  • D'Elia M; CeresMed, South Burlington, VT, USA.
  • Aldrich J; Hereditary Neuropathy Foundation, New York, NY, USA.
  • Moore RN; Hereditary Neuropathy Foundation, New York, NY, USA.
  • Moore AT; Hereditary Neuropathy Foundation, New York, NY, USA.
  • Piper BJ; Department of Medical Education, Geisinger Commonwealth School of Medicine, Scranton, PA, USA.
Am J Hosp Palliat Care ; 40(11): 1163-1167, 2023 Nov.
Article en En | MEDLINE | ID: mdl-36793224
Objective: Chronic pain is a major problem for patients with Charcot-Marie-Tooth (CMT) disease. This exploratory study examined patient reported efficacy of medical cannabis for pain management in this population. Methods: Participants (N = 56; 71.4% female; Age = 48.9, SD = 14.6; 48.5% CMT1) were recruited though the Hereditary Neuropathy Foundation. The online survey contained 52 multiple choice questions about demographics, medical cannabis use, symptomology, efficacy, and adverse effects. Results: Nearly all (90.9%) of respondents reported experiencing pain, including all (100%) females and 72.7% of males (chi-square P < .05) with 91.7% of respondents indicating cannabis provided at least 50% pain relief. The most frequent response was an 80% reduction in pain. Moreover, 80.0% of respondents reported using less opiates, 69% noted using less sleep medication, and 50.0% reported using less anxiety/antidepressant medications. Negative side effects were noted by 23.5% of respondents. However, almost all (91.7%) of that subgroup did not have plans to stop consuming cannabis. One-third (33.9%) possessed a medical cannabis certificate. Patient perceptions of their physicians' attitudes regarding patient medical cannabis use greatly impacted whether respondents informed their providers of their usage. Conclusion: The vast majority of patients with CMT reported that cannabis was effective to manage pain symptoms. These data support the need for prospective, randomized, controlled trials using standardized dosing protocols to further delineate and optimize the potential use of cannabis to treat pain related to CMT.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Cannabis / Enfermedad de Charcot-Marie-Tooth / Dolor Crónico / Marihuana Medicinal Tipo de estudio: Clinical_trials Aspecto: Patient_preference Límite: Female / Humans / Male / Middle aged Idioma: En Revista: Am J Hosp Palliat Care Asunto de la revista: ENFERMAGEM Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Cannabis / Enfermedad de Charcot-Marie-Tooth / Dolor Crónico / Marihuana Medicinal Tipo de estudio: Clinical_trials Aspecto: Patient_preference Límite: Female / Humans / Male / Middle aged Idioma: En Revista: Am J Hosp Palliat Care Asunto de la revista: ENFERMAGEM Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos